Sanofi Revenue 2006-2019 | SNY

Sanofi annual/quarterly revenue history and growth rate from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Sanofi revenue for the quarter ending September 30, 2019 was $11.032B, a 4.35% increase year-over-year.
  • Sanofi revenue for the twelve months ending September 30, 2019 was $30.917B, a 24.45% decline year-over-year.
  • Sanofi annual revenue for 2019 was $42.147B, a 0.03% increase from 2018.
  • Sanofi annual revenue for 2018 was $42.135B, a 2.96% increase from 2017.
  • Sanofi annual revenue for 2017 was $40.921B, a 6.54% increase from 2016.
Sanofi Annual Revenue
(Millions of US $)
2019 $42,147
2018 $42,135
2017 $40,921
2016 $38,408
2015 $38,710
2014 $45,341
2013 $44,240
2012 $46,244
2011 $48,829
2010 $42,539
2009 $42,883
2008 $42,398
2007 $40,034
2006 $37,044
2005 $35,510
Sanofi Quarterly Revenue
(Millions of US $)
2019-09-30 $11,032
2019-06-30
2019-03-31 $9,896
2018-03-31 $9,988
2017-12-31 $10,572
2017-09-30 $11,040
2017-06-30 $9,828
2017-03-31 $9,482
2016-12-31 $9,904
2016-09-30 $10,373
2016-06-30 $9,385
2016-03-31 $8,746
2015-09-30 $10,770
2015-06-30 $10,466
2014-06-30 $11,175
2013-06-30 $10,560
2012-06-30 $11,716
2012-03-31 $11,247
2011-12-31 $11,701
2011-09-30 $12,087
2011-06-30 $12,061
2011-03-31 $11,423
2010-12-31 $10,075
2010-09-30 $10,788
2010-06-30 $10,648
2010-03-31 $9,748
2009-12-31 $10,098
2009-09-30 $10,922
2009-06-30 $10,582
2009-03-31 $9,190
2008-12-31 $9,834
2008-09-30 $10,127
2008-06-30 $10,407
2008-03-31 $10,519
2007-12-31 $10,366
2007-09-30 $10,133
2007-06-30 $9,356
2007-03-31 $9,737
2006-12-31 $9,489
2006-09-30 $8,848
2006-06-30 $8,897
2006-03-31 $8,463
2005-12-31 $8,342
2005-09-30 $8,784
2005-06-30 $8,430
2005-03-31 $8,419
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $111.910B $40.002B
Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $350.661B 15.32
Roche Holding AG (RHHBY) Switzerland $279.966B 0.00
Merck (MRK) United States $195.166B 14.83
Novartis AG (NVS) Switzerland $187.698B 15.63
Pfizer (PFE) United States $181.241B 11.07
Novo Nordisk (NVO) Denmark $142.506B 24.46
Eli Lilly (LLY) United States $132.492B 22.92
Bristol-Myers Squibb (BMY) United States $122.786B 11.65
AstraZeneca (AZN) United Kingdom $116.863B 25.16
AbbVie (ABBV) United States $111.105B 8.42
GlaxoSmithKline (GSK) United Kingdom $93.822B 11.90
Bayer (BAYRY) Germany $54.386B 7.84
H Lundbeck (HLUYY) Denmark $5.767B 10.02
Innoviva (INVA) United States $1.178B 8.13